Draft WHO Guidance Provides Two Pathways For Biosimilars
Executive Summary
Clinical trials would be required for most biosimilars under two approval scenarios that are being developed by the World Health Organization
You may also be interested in...
Biosimilars Pathway In WHO Draft Guidance Drops Dual-track Approach
A World Health Organization working group dropped the less rigorous of two approaches for regulating biosimilars from its latest draft guidelines, a positive step, according to generic drug maker Sandoz
Biosimilars Pathway In WHO Draft Guidance Drops Dual-track Approach
A World Health Organization working group dropped the less rigorous of two approaches for regulating biosimilars from its latest draft guidelines, a positive step, according to generic drug maker Sandoz
Biosimilars Guidance By WHO To Be Redrafted To Clarify Data Requirements
The World Health Organization's draft guidelines for approving biosimilars will undergo another round of revisions following their review by the WHO Expert Committee on Biological Standardization